

CITATION REPORT

List of articles citing

Selectivity of sildenafil and other phosphodiesterase type 5 (PDE5) inhibitors against all human phosphodiesterase families

DOI: 10.1016/s1569-9056(02)80240-8
European Urology Supplements, 2002, 1, 63.

Source: <https://exaly.com/paper-pdf/34230033/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
41	Viagra (sildenafil citrate) and ophthalmology. <i>Progress in Retinal and Eye Research</i> , 2002 , 21, 485-506	20.5	104
40	Sustained efficacy and tolerability with vardenafil over 2 years of treatment in men with erectile dysfunction. <i>International Journal of Clinical Practice</i> , 2004 , 58, 230-9	2.9	69
39	Erectile response with vardenafil in sildenafil nonresponders: a multicentre, double-blind, 12-week, flexible-dose, placebo-controlled erectile dysfunction clinical trial. <i>BJU International</i> , 2004 , 94, 1301-9	5.6	59
38	Potency, selectivity, and consequences of nonselectivity of PDE inhibition. <i>International Journal of Impotence Research</i> , 2004 , 16 Suppl 1, S11-4	2.3	165
37	Review of phosphodiesterases in the urogenital system: new directions for therapeutic intervention. <i>Journal of Sexual Medicine</i> , 2004 , 1, 322-36	1.1	29
36	Phosphodiesterase Type-5 Inhibitors: A Critical Comparative Analysis. <i>EAU Update Series</i> , 2004 , 2, 56-63		17
35	[Recent progress in cyclic nucleotide phosphodiesterase research: isozymes, functions, and inhibitors]. <i>Folia Pharmacologica Japonica</i> , 2005 , 126, 121-7	0	6
34	Vardenafil in the treatment of erectile dysfunction: a review of clinical data. <i>Aging Health</i> , 2005 , 1, 367-377		1
33	Past, present, and future: a 7-year update of Viagra (sildenafil citrate). <i>International Journal of Clinical Practice</i> , 2005 , 59, 680-91	2.9	61
32	High biochemical selectivity of tadalafil, sildenafil and vardenafil for human phosphodiesterase 5A1 (PDE5) over PDE11A4 suggests the absence of PDE11A4 cross-reaction in patients. <i>International Journal of Impotence Research</i> , 2005 , 17, 5-9	2.3	50
31	Comment on: Inhibition of phosphodiesterase 11 (PDE11) impacts on sperm quality. <i>International Journal of Impotence Research</i> , 2005 , 17, 387-387	2.3	
30	Vardenafil for the treatment of erectile dysfunction: a critical review of the literature based on personal clinical experience. <i>European Urology</i> , 2005 , 47, 612-21	10.2	31
29	Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction. <i>World Journal of Urology</i> , 2005 , 23, 374-84	4	25
28	Drug Insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction. <i>Nature Reviews Urology</i> , 2005 , 2, 239-47		40
27	Oral Therapy for Erectile Dysfunction. 2006 , 271-286		
26	Vardenafil rescue rates of sildenafil nonresponders: objective assessment of 327 patients with erectile dysfunction. <i>Urology</i> , 2006 , 68, 397-401	1.6	12
25	Pde9. 2006 ,		1

24	Phosphodiesterase 11: a brief review of structure, expression and function. <i>International Journal of Impotence Research</i> , 2006 , 18, 501-9	2.3	47
23	Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future. <i>European Urology</i> , 2006 , 50, 1194-207; discussion 1207	10.2	74
22	Alterations in sperm motility after acute oral administration of sildenafil or tadalafil in young, infertile men. <i>Fertility and Sterility</i> , 2007 , 88, 860-5	4.8	56
21	N-Terminal domain of phosphodiesterase-11A4 (PDE11A4) decreases affinity of the catalytic site for substrates and tadalafil, and is involved in oligomerization. <i>Biochemistry</i> , 2007 , 46, 10353-64	3.2	31
20	Applications of ion associates for the microdetermination of vardenafil using atomic emission spectrometry. <i>Mikrochimica Acta</i> , 2007 , 158, 233-238	5.8	5
19	[The basics of phosphodiesterase type 5 (PDE5) inhibition in urology]. <i>Der Urologe</i> , 2008 , 47, 1582-7		3
18	[Impact of the pharmacokinetic properties of PDE5 inhibitors on the dose/sexual intercourse interval]. <i>Progres En Urologie</i> , 2008 , 18, 536-42	0.9	2
17	Comparative relaxing effects of sildenafil, vardenafil, and tadalafil in human corpus cavernosum: contribution of endogenous nitric oxide release. <i>Urology</i> , 2009 , 74, 216-21	1.6	10
16	Phosphodiesterase 5 Inhibitors to Treat Erectile Dysfunction. 2010 , 135-172		
15	The recent phosphodiesterase type 5 inhibitors. <i>Human Andrology</i> , 2012 , 2, 57-64	1	
14	Phosphodiesterase inhibitors in clinical urology. <i>Expert Review of Clinical Pharmacology</i> , 2013 , 6, 323-32	3.8	20
13	Characterization of TPN729 metabolites in humans using ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016 , 117, 217-26	3.5	10
12	Pharmacokinetics-Driven Optimization of 4(3 H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension. <i>Journal of Medicinal Chemistry</i> , 2019 , 62, 4979-4990	8.3	13
11	Liquid chromatography-tandem mass spectrometric assay for TPN171 in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020 , 191, 113634	3.5	1
10	The Use of Vasoactive Drugs in the Treatment of Male Erectile Dysfunction: Current Concepts. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	5
9	Discovery of highly selective and orally available benzimidazole-based phosphodiesterase 10 inhibitors with improved solubility and pharmacokinetic properties for treatment of pulmonary arterial hypertension. <i>Acta Pharmaceutica Sinica B</i> , 2020 , 10, 2339-2347	15.5	9
8	cGMP signalling in dorsal root ganglia and the spinal cord: Various functions in development and adulthood. <i>British Journal of Pharmacology</i> , 2021 ,	8.6	0
7	Sildenafil in the treatment of erectile dysfunction: an overview of the clinical evidence. <i>Clinical Interventions in Aging</i> , 2006 , 1, 403-14	4	36

6 Sildenafil Citrate and the Nitric Oxide/Cyclic Guanosine Monophosphate Signaling Pathway. **2004**, 89-116

5 Pde11. **2006**,

4 Treatment of Erectile Dysfunction in Chronic Kidney Disease. **2008**, 783-790

3 The Utility of PDE5 Inhibitors After Radical Prostatectomy. **2009**, 177-196

2 Phosphodiesterase-9A. **2010**, 1589-1593

1 Pharmacokinetics, mass balance, and metabolism of [14C]TPN171, a novel PDE5 inhibitor, in humans for the treatment of pulmonary arterial hypertension. *Acta Pharmacologica Sinica*,

8

1